T1	Participants 95 174	a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
T2	Participants 326 460	safety and immunogenicity of the monovalent, recombinant, chimpanzee adenovirus type-3 vector-based Ebola Zaire vaccine (ChAd3-EBO-Z).
T3	Participants 565 628	Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
T4	Participants 643 691	(aged 18-65 years) were randomly assigned (2:2:1
T5	Participants 1417 1458	safety and immunogenicity of ChAd3-EBO-Z.
T6	Participants 1528 1566	ClinicalTrials.gov, number NCT02289027
T7	Participants 1585 1813	Oct 24, 2014, and June 22, 2015, we randomly assigned 120 participants, of whom 18 (15%) were potentially deployed and 102 (85%) were non-deployed, to receive high-dose vaccine (n=49), low-dose vaccine (n=51), or placebo (n=20).
T8	Participants 1848 1856	6 months
T9	Participants 3367 3469	ChAd3-EBO-Z was safe and well tolerated, although mild to moderate systemic adverse events were common
T10	Participants 3471 3533	A single dose was immunogenic in almost all vaccine recipients
T11	Participants 3613 3688	significant difference between doses for safety and immunogenicity outcomes
T12	Participants 3565 3599	significantly present at 6 months.
T13	Participants 3763 3808	phase 2 and phase 3 efficacy trials in Africa
T14	Participants 3818 3887	Swiss State Secretariat for Education, Research and Innovation (SERI)
